Jack Kenny joined the board in September 2024 and serves on the Nominating and Corporate Governance Committee. He has more than 30 years of experience with leadership roles in the in vitro diagnostics, anatomic pathology, molecular, microbiology, and lab services industries. Mr. Kenny previously served as Meridian Bioscience’s Chief Executive Officer. During his time there built the company into a strong performer, growing consistently above market growth in sales and earnings, and bolstered its product line. Before his tenure at Meridian, Mr. Kenny served as Senior Vice President and General Manager, North America, with Siemens Healthcare and as Vice President and General Manager, U.S. Region, for Becton Dickinson, Diagnostic Systems. Prior to that, he held executive roles at Danaher Corporation and Quest Diagnostics. His experience spans marketing, product launches, portfolio planning, lifecycle management, new product development, and mergers and acquisitions. Mr. Kenny currently is an independent director on the Board of Directors for Quantum Si (Nasdaq: QSI) and DCN Dx (privately held by Martis Capital).  He holds a bachelor’s degree in management from Kettering University.